Metsera (NASDAQ:MTSR – Get Free Report) issued its quarterly earnings results on Wednesday. The company reported ($3.52) earnings per share for the quarter, Zacks reports.
Metsera Stock Performance
NASDAQ:MTSR opened at $30.01 on Friday. Metsera has a twelve month low of $23.08 and a twelve month high of $32.81.
Wall Street Analysts Forecast Growth
A number of research firms have weighed in on MTSR. Bank of America assumed coverage on shares of Metsera in a report on Tuesday, February 25th. They set a “buy” rating and a $38.00 price target for the company. Evercore ISI began coverage on shares of Metsera in a research note on Tuesday, February 25th. They set an “outperform” rating for the company. Cantor Fitzgerald started coverage on shares of Metsera in a research report on Tuesday, February 25th. They set an “overweight” rating on the stock. Finally, Guggenheim started coverage on Metsera in a report on Tuesday, February 25th. They set a “buy” rating and a $56.00 price target for the company.
About Metsera
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
Further Reading
- Five stocks we like better than Metsera
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- 3 Momentum Stocks Near 52-Week Highs to Watch for More Growth
- Growth Stocks: What They Are, Examples and How to Invest
- Microsoft’s Big Malaysia Bet Could Pay Off for Investors
- Dividend Capture Strategy: What You Need to Know
- The 5 Most Oversold Stocks on the Market Are…
Receive News & Ratings for Metsera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metsera and related companies with MarketBeat.com's FREE daily email newsletter.
